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Highlights 
• 
We examine two strategies of monitoring in cirrhotics treated with variceal ligation. 
• 
The incidence of variceal recurrence and bleeding is the same at 3 and 6 months. 
• 
Endoscopic control at 3 months after eradication does not influence the outcome. 
• 
Endoscopic control twice a year after variceal eradication is cost-effective. 
 
Abstract 
Background and objectives 
Endoscopic variceal ligation (EVL) is recommended to treat esophageal varices (EV) in cirrhosis 
and portal hypertension. A program of endoscopic surveillance is not clearly established. The aim 
of this prospective randomized trial was to assess the most effective timing of endoscopic 
monitoring after variceal eradication and its impact on the patient's outcome and on the costs. 
Methods 
A hundred and two cirrhotic patients with esophageal varices treated by EVL were evaluated. After 
variceal eradication patients were randomized to receive first endoscopic control at 3 (Group 1) and 
6 (Group 2) months respectively. 
Results 
Variceal obliteration was achieved in all patients. Variceal recurrence was observed in 28 cases at 
the first control (29.1%) without difference between the two groups (32% vs 29% in group 1 and 2 
respectively, p = 0.75). The incidence of large varices is similar in the two groups (33% vs 38% 
respectively). Using a multivariate analysis, medical therapy with B blockers was the only 
independent predictor of lowest risk of variceal recurrence [OR 2.30, 95% CI (1.68–3.26)]. 
Bleeding related to recurrent varices occurred in 3.1% of cases and was associated with portal 
thrombosis. Child Pugh score ≥ 8 was the only predictor of mortality (p = 0.0002). 
Conclusions 
Recurrence of varices after banding ligation is not rare but it is associated with a low risk of variceal 
progression and bleeding. Accordingly, a first endoscopic control at 6 months after variceal 
eradication associated with a good risk stratification might be a cost-effective strategy of 
monitoring. 
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1. Introduction 
Esophageal variceal (EV) bleeding is a severe complication in the cirrhotic patient's life and 
represents a change in the clinical evolution of the liver disease (1) and (2). Esophageal varices are 
present in about 60% of patients with an end-stage cirrhosis and in about 30% of patients with 
compensated cirrhosis (3). About one-third of patients with cirrhosis and esophageal varices 
experience bleeding in the course of the disease with a 20–30% mortality rate (4). After an initial 
bleeding from EV, re-bleeding occurs in about 60% of the patients; for this all cirrhotic patients 
who survive a bleeding event have to undergo secondary prophylaxis to prevent rebleeding 
(5) and (6). Endoscopic Variceal Ligation (EVL) is used to prevent and treat esophageal variceal 
bleeding (6), (7) and (8). It has a recognized role in primary prophylaxis in naive patients with a 
high risk of bleeding for Child and size of varices or for intolerance to treatment with β-blockers. 
Current guidelines recommend EVL combined with B blockers to prevent variceal rebleeding and 
to reduce bleeding related mortality(5), (9), (10), (11), (12) and (13). Even though the EVL is 
routinely used in clinical practice and considered a safe procedure with few treatment-related 
complications, there are no specific guidelines regarding the technical aspects such as the number of 
bands placed per session or the intervals between sessions and the endoscopic surveillance after 
eradication. Some authors suggest that the placement of more than 6 bands at any given session is 
associated with a higher risk of endoscopic complications and does not reduce the time to achieve 
obliteration (14) and (15). An interbanding interval < 3 weeks seems to increase the risk of 
rebleeding (14). In our previous experience we reported that a longer interbanding interval 
(> 20 days) reduces the incidence of treatment-related complications and the number of missing 
endoscopies (14). About the endoscopic monitoring after eradication, the current indications 
suggest an endoscopy performed after one, three and six months from variceal eradication but the 
timing is variable according to the different experiences and the clinical impact of this close 
monitoring is also unclear (16), (17) and (18). 
The main purpose of this prospective randomized study was to assess if the introduction of an early 
endoscopic control 3 months after variceal eradication was convenient and cost effective in order to 
prevent variceal recurrence and bleeding. Once the eradication was reached, the patients were 
randomized to receive an endoscopic control at 3 and 6 months (group 1) or only at 6 months 
(group 2). The impact of these different monitoring strategies on endoscopic therapy and on 
variceal bleeding was evaluated. The direct medical costs of the management for both groups were 
calculated using the Italian Health Service tariffs. 
2. Materials and methods 
2.1. Patients 
A hundred and twelve consecutive cirrhotic patients with portal hypertension referred between 
January 2010 and June 2011 to our Endoscopic Operative Unit for banding ligation were included 
for study. Patients with clinical evidence of advanced hepatocellular carcinoma, previous surgical or 
endoscopic treatment for esophageal varices, fundal varices were excluded. The study was made on 
102 patients and approved by the Ethics Committee of S. Giovanni Battista Hospital. An informed 
consent was given by each included patient. 
2.2. Methods 
Patients with active esophageal variceal bleeding underwent emergent EVL or sclerosis and 
received iv vasoactive drugs. B-blockers were started if the patient was not treated. Patients with 
recent esophageal variceal bleeding underwent elective EVL. Variceal bleeding was defined as a 
new onset of hematemesis or melena with evidence of active bleeding from the varix or when a clot 
was seen adherent to a varix and no other cause of bleeding from the gastrointestinal tract was 
evident. 
EVL was performed in primary prophylaxis in patients with high risk of bleeding from esophageal 
varices (Child C or small varices with red signs) and with intolerance or contraindications to use of 
B blockers. Among 32 patients with high risk varices, despite the use of B blockers, EVL was 
introduced in 17 of them waiting for liver transplant, in 6 candidates to locoregional therapy for 
hepatocellular carcinoma, and in 9 who needed anticoagulation therapy for portal thrombosis. In the 
total number of patients EVL treatment was continued so as to achieve variceal eradication. 
EVL was performed with endoscopic multiband ligator (Wilson Cook Medical Inc., Winston Salem 
NC; Ireland) and a sedation with midazolam was used prior to endoscopy. The varices were ligated 
about 1–2 cm above the gastroesophageal junction applying one or two bands for each variceal 
column. The severity of esophageal varices was graded as F1: small, straight varices; F2: enlarged 
and tortuous varices (less than 1/3 of the lumen); F3: large and coil-shaped varices (more than 1/3 
of the lumen) (19). The treatment scheduled involved a session every 20–30 days until variceal 
eradication; this timing was chosen on the basis of previous experience (14). The patients missing 
more than two consecutive sessions were excluded from the study. 
Varices were considered eradicated when absent or venous ectasias smoothed out completely with 
air insufflation were found. Variceal recurrence was defined as the reappearance of varices which 
could be treated by new ligation. 
When obliteration of varices was obtained, the patients were randomized to undergo endoscopic 
control after 3 and 6 months (Group 1) or after 6 months only (Group 2). The following endoscopic 
controls were performed every 6 months in both groups to monitor variceal recurrence (Fig. 1). 
Variceal eradication and variceal recurrence had to be agreed upon by two experienced 
endoscopists. 
 
Fig. 1.  
Trial flow chart. 
 
2.3. Design of the study 
According to the published data about the variceal recurrence after banding ligation, we 
hypothesized that about 45% of treated patients develop new varices during the follow up with an 
incidence in the first 6 months after eradication between 10 and 25% (20), (21), (22), (23) and (24). 
On the assumption of a minimal 10% difference between 3 and 6 months in terms of variceal 
recurrence, the simple size was calculated as 46 patients in each treatment group, using a 2-side test 
with 80% of the study power and an alpha error of 0.05. 
Randomization was done by computer and was kept in consecutively numbered opaque envelopes 
used when the group was assigned. 
2.4. Statistical analysis 
Categorical variables were compared using the χ2 test and Fisher test when appropriate, the 
continuous variable using unpaired Student's T-test. Logistic regression was used to evaluate the 
relationship between the presence of variceal esophageal recurrence (no/yes = 0/1) as the dependent 
variable and possible predictors as the independent variables. The model was estimated using the 
stepwise backward method. In the multivariate analysis we used the variable that resulted in 
statistically significant difference in univariate examination using a non parametric analysis like the 
Mann–Whitney test. We performed a survival analysis between the two follow-up variables (3 vs 
6 months) using the Kaplan–Meier estimates of survival, and the difference between curves was 
calculated with Log-Rank and Wilcoxon test. We performed a Cox (Proportional Hazard) 
Regression to evaluate a relationship between survival and predictors that resulted to have a 
significant difference in univariate analysis. A two-tailed P-value of 0.05 or less was considered 
significant. All analyses were performed using StatsDirect Statistical Software version 3.0.86 
except for the Cox Regression, which was calculated with MedCalc version 10.2. The results were 
expressed as range and median. The Kappa-statistic was used for agreement analysis between 
observers with regard to the eradication and recurrence of esophageal varices. 
3. Results 
A total of 102 patients participated in the study. Six patients had to be excluded because they 
dropped out before reaching the eradication or had undergone liver transplantation. Therefore, 
ninety-six patients were treated until variceal eradication and had regular follow-up (73.02 to 
91.27 months, mean survival time 82.15). Chronic viral hepatitis alone or in combination with 
alcohol was the most common cause of portal hypertension and esophageal varices (89%). Sixty-
two patients underwent EVL for primary prophylaxis and another 34 after an episode of esophageal 
variceal bleeding. Twenty-four patients were actively bleeding at the time of their first EVL session. 
Forty-eight patients received a first endoscopic control after 3 months from variceal eradication 
(Group 1) and the other 48 after 6 months (Group 2). The two groups were comparable for gender, 
age, etiology of cirrhosis, Child–Pugh classification and grade of the EV (Table 1). The patients 
treated in primary prophylaxis were not different in terms of bleeding risk from patients receiving 
EVL in secondary prophylaxis (Table 2). It's important to notice that one patient per group had 
small varices without red signs and received EVL before being treated for portal thrombosis. 
Table 1.  
Clinical and endoscopic characteristics of the patients at the time of first endoscopy. 
 Group 1 
(3 months) 
Group 2 
(6 months) 
p 
Number of patients 48 48 
 
 Age (years) 60 (48–84) 59 (37–81) 0.91 
 Gender (male/female) 34/14 37/11 0.87 
 Etiology of portal hypertension: (n%) 
   
 Viral 25/52% 27/56% 0.93 
 Alcoholic 10/21% 12/25% 0.93 
 Vascular disease 4/8% 1/2% 0.86 
 Viral + alcoholic 5/11% 6/13% 0.91 
 Other 4/8% 2/4% 0.75 
Child–Pugh: (n/%) 
   
 A 31/65% 24/50% 0.73 
 B 16/33% 18/37% 0.76 
 C 1/2% 6/13% 0.84 
EV: (n/%) 
   
 F1 2/4% 4/8% 0.73 
 F2 29/61% 32/67% 0.72 
 F3 17/35% 12/25% 0.87 
Red signs (n/%) 31/65% 27/56% 0.88 
β-blockers (n/%) 31/65% 29/61% 0.89 
Diabetes mellitus (n/%) 11/23% 8/17% 0.87 
Primary prophylaxis (n/%) 34/71% 28/58% 0.66 
Secondary prophylaxis (n/%) 14/29% 20/42% 0.73 
Actively bleeding (n/tot) 11/14 13/20 0.81 
 
Table 2.  
Distribution of risk factors of variceal hemorrhage in patients receiving EVL in primary and 
secondary prophylaxis. 
 
Primary prophylaxis 
(62) 
Secondary prophylaxis 
(34) 
p 
Child C 4/62 (6.4%) 2/34 (5.8%) 0.94 
Red wale signs on varices 
(RWS) 
38/62 (61%) 20/34 (58%) 0.98 
B blockers 32/62 (51%) 28/34 (82%) 0.002 
Large varices 59/62 (95%) 31/34 (91%) 0.47 
Small varices with RWS 2/62 (3.2%) 2/34 (5.8%) 0.57 
Session ≥4 15/62 (24%) 3/34 (8.8%) 0.06 
 
Variceal eradication was achieved in all treated patients. The median number of sessions of EVL 
required to achieve variceal obliteration was 3 ± 1.28 for the Group 1 and 2 ± 1.21 for the Group 2. 
The median number of bands per session was 4 ± 1.06 for the Group 1 and 3.5±1.33 for the Group 
2. The interval between sessions was 28 days for Group 1 and 30 for Group 2. Eighteen patients 
(18.7%), 11/48 (22.9%) in Group 1 and 7/48 (14.5%) in Group 2 received ≥ 4 sessions of EVL. The 
difference between the two groups for each parameter was not statistically significant (Table 3). 
Patients with large esophageal varices required more sessions (≥ 3) than patients with small varices 
to obtain eradication (22/28 vs 25/68, p = 0.0004) but the number of sessions did not influence 
significantly the incidence of variceal recurrence (p = 0.05). Esophageal ulcers resulting from each 
EVL session were found during the examination in 3% of the patients (2 in Group 1 and 1 in Group 
2). In two of these patients a bleeding episode occurred within the first three weeks, before the 
varices could be eradicated. The bleeding originated from post-ligation ulcer caused melena and 
anemia but did not require endoscopic treatment. The presence of ulcers delayed the following 
session of banding in all cases. No stricture formation, aspiration pneumonia, or perforation 
occurred. Transient dysphagia was occasional. 
Table 3.  
Number of sessions of EVL, number of bands per session, interval between sessions in two 
groups of patients. 
 
Group 1 (48) Group 2 (48) p 
Number of sessions of EVL required (mean) 3 (range 1–5) 2 (range 1–6) 0.97 
Bands per session (mean) 4 (range 2–7) 3.5 (range 1–6) 0.96 
Interval between sessions (mean) 28 (range 20–36) 30 (range 21–34) 0.25 
Session ≥4 17/48 7/48 0.31 
 
Four patients died within two months after eradication: one, a Child Pugh's C patient, in Group 1 
and 3 patients (Child Pugh's B/C, 1/2 respectively) in Group 2. The mortality was unrelated to 
bleeding events. These patients were excluded from the analysis of variceal recurrence. 
Recurrence of varices after endoscopic banding was observed in 28 cases at the first control 
(29.1%) without difference between the two groups (32% vs 29% in Groups 1 and 2 respectively, 
p = 0.753). In these patients the incidence of large varices was not different after 3 and 6 months 
being 5 cases out of 15 (33%) in Group 1 and 5 cases out of 13 (38%) in Group 2, suggesting a low 
risk of progression of EV after a new formation. When variceal recurrence was diagnosed, 10/15 
patients in Group 1 and 10/13 patients in Group 2 received a new treatment of EVL at the same 
time of diagnosis (67% vs 77% respectively, p = 0.5) (Table 4). The kappa index regarding the 
interobserver agreement rate for eradication and recurrence was 0.89 and 0.85 respectively. 
Table 4.  
Recurrence of EV, incidence of large varices at the first control after eradication and early 
treatment of newly formed EV during the follow up in both groups. 
 
Group 1 (47) Group 2 (45) p 
Recurrence of EV 15/47 (32%) 13/45 (29%) 0.75 
Incidence of large varices 5/15 (33%) 5/13 (38%) 0.81 
Early treatment of newly formed EV 10/15 (67%) 10/13 (77%) 0.45 
 
We analyzed the incidence of EV recurrence according to the etiology of cirrhosis. Compatible with 
the small sample size, there were no differences when comparing the number of patients with 
variceal recurrence for each etiology (viral, alcohol, viral + alcohol). Similarly we did not observe 
any difference in the incidence of variceal recurrence in patients with viral cirrhosis when compared 
to alcoholic or viral + alcoholic patients (viral vs alcohol, 24/52 vs 11/22, p = 0.80, viral vs 
viral + alcohol, 24/52 vs 7/18, p = 0.78). Using a multivariate analysis, medical therapy with B 
blockers was the only independent predictor associated with a lower risk of variceal recurrence [OR 
2.30, 95% CI (1.68–3.26)]. 
Three patients had variceal rebleeding during the follow-up: two of these have developed portal 
thrombosis and one advanced hepatocellular carcinoma. None of them died of variceal bleeding. No 
bleeding event occurred between 3 and 6 months in Group 2. There was no mortality difference 
between the two groups (mean survival time 42.22 months in Group 1 and 39.92 in Group 2, 
p = 0.09). Kaplan–Meier survival is presented in Fig. 2. Liver failure was the only predictor of 
mortality: Child Pugh's score ≥ 8 was associated with a higher risk of mortality (RR 2.49, 
p = 0.0002) as presented in Fig. 3. This explains the apparent worse survival in Group 2 in which 
there were more patients with advanced liver disease. 
 
Fig. 2.  
Probability of survival in each group of patients. The difference between two groups is not 
statistically significant (p = 0.09). 
 
 
Fig. 3.  
Survival probability related to liver failure in two groups of patients. The mortality in 
patients with Child Pugh's score > 8 is significantly higher (p = 0.0002). 
 
The summary of the costs in the two treatment strategies is shown in Table 5. Medical costs 
sustained by health-care providers were related to visit, endoscopy and 1-day hospital stay. 
Table 5.  
Summary of direct costs of treatment in patients allocated to 3 months (Group 1) and 
6 months (Group 2) for the first endoscopy. 
Patients 
Group 1 (3 months) Group 2 (6 months) 
47 pts 45 pts 
Endoscopy + visit 3272 3133 
EVL treatment (a) 5850 4875 
Total 12395 (b) 8009 
a 
Including the costs of 1 day hospital stay + 1 day work lost. 
b 
Including the costs of endoscopy + visit repeated at 6 months in all patients. 
 
4. Discussion 
The indications for EVL include primary prophylaxis, episodes of variceal bleeding and rebleeding 
(5) and (6). It might be considered in patients with high risk of variceal bleeding (Child C patients 
with small varices with red signs or Child A/B with large varices). In these patients, EVL is an 
alternative to β-blockers when the pharmacological treatment is contraindicated or not tolerated 
(25) and (26). In patients who had acute variceal hemorrhage EBL combined with β-blockers is 
indicated to prevent rebleeding (27) and (28). Compared with sclerotherapy, EVL is equally 
effective in controlling active esophageal variceal bleeding but it is associated with a lower rate of 
rebleeding and complications (29) and (30). 
Although banding ligation has become the endoscopic treatment of choice for esophageal varices, 
there is still a wide disparity in technical approach and an optimal program of endoscopic 
surveillance is not standardized. For a long time, the discussion has been focused on the technical 
aspects such as the number of bands to be placed in every session and the time interval between 
sessions. About the first point, we know that the number of bands placed in every session does not 
influence the time required to achieve the variceal obliteration. Particularly, six bands per session 
should be the optimal cut-off number to reduce the procedure time and the side effects as dysphagia 
or chest pain. A higher number of bands does not reduce the time to obliteration and increases the 
complications (15). Our experience confirms the effectiveness of this approach. The mean number 
of bands per session was < 5 in all patients with a low incidence (3%) of complications. No severe 
dysphagia, perforation or stricture formation was encountered. 
The time interval between sessions is another relevant topic. The success of EVL is closely related 
to the duration of time needed to reach the variceal obliteration. An interval of 2 months suggested 
by some authors is not feasible because associated with a high variceal bleeding rate between 
sessions (31). On the other hand, a too short interval (1 or 2 weeks) increases the incidence of ulcers 
present after every session and the risk of having to postpone the EVL because ulcers preclude the 
placement of bands (14) and (20). Based on our previous experience, in our current clinical practice 
the sessions are scheduled at 4 week intervals. With this approach we have had to defer variceal 
ligation in only 3% of treated patients and we observed episodes of bleeding in only 2 patients 
before achieving variceal obliteration. 
However, an optimal surveillance program after variceal obliteration is yet to be established. Even 
if eradication can be obtained with ligation in more than 90% of patients, the frequency of variceal 
recurrence is high (20), (21), (22), (23) and (24). Since the recurrence is early reaching up to 48% 
within the first year in many series, some authors have suggested the need for close endoscopic 
control after eradication (every 3 months) through the first year of follow-up (32). The current 
indications recommend control of patients after 1 and 3 months after eradication (17). However, 
such monitoring requires significant consumption of resources and has an important impact on the 
quality of the patient's life (loss of working days, anxiety, discomfort). In view of this, we must 
consider that against a high recurrence rate, the variceal bleeding from recurrent varices is very low, 
increasing significantly one year after eradication (24). The rebleeding is mostly related to the 
ulcers post treatment and the liver reserve. Child's C patients ran a higher risk of rebleeding 
compared with Child A (29), (30) and (33). 
The main goal of our study has been just to define the optimal timing of endoscopic control after 
eradication. Variceal eradication has to be documented before beginning the follow up to avoid 
confusion between variceal recurrence and residual varices. On reaching this step, considering that 
the first control after 1 month was not cost-effective (one hundred procedures to diagnose < 5% of 
recurrent varices), the patients were randomized to receive the first control after 3 and 6 months. 
We observed a relatively early recurrence of esophageal varices, around 35% in the first 6 months. 
This incidence is similar to the results reported by other studies in which the variceal recurrence rate 
after EVL is variable from 20 to 38%, until 47% after 1 year (22), (23), (24) and (34). Only the 
medical therapy with B blockers appears protective against variceal recurrence when associated 
with EVL. 
The number of patients controlled after 6 months who presented newly formed varices is not 
different from that of patients evaluated after 3 months. Of note is the fact that there was no 
significant difference between the two groups for the presence of large varices, pointing out the 
absence of a rapid progression of new EV. Moreover, despite early reappearance of EV, one-third 
of the patients in Group 1 did not undergo an early EVL retreatment; this, in part, because the 
banding of small varices may not be feasible in the context of scarring. None of these patients bled 
during the following 6 months. Thus we can assume that the early recurrence of varices is not 
associated with clinical events (20). The mortality in patients who received EVL for esophageal 
variceal bleeding appears related to severity of liver disease more than to variceal recurrence or 
variceal bleeding. 
Costs were higher for the Group 1 than for the Group 2 strategy. In Group 1 more than 100 
procedures were performed to treat 13% of the patients. The approach with the first endoscopic 
control after 6 months was cost-effective reducing the number of endoscopies by 45–50% whereas 
the incidence of bleeding and mortality was not influenced. 
Summarizing, this study showed that, despite an early rate of variceal recurrence after EVL, the 
variceal progression rate is low and the variceal rebleeding rare. Even if preliminary, these 
observations seem to indicate that a close endoscopic monitoring after variceal obliteration did not 
add value to the outcome or treatment, did not influence the prognosis of the patient and was not 
cost-effective. Endoscopic control twice a year after variceal eradication might be optimal. The 
timing should be adapted to each patient considering several factors able to influence variceal 
recurrence and bleeding as liver function, the appearance of portal thrombosis or hepatocellular 
carcinoma and the presence of red wale markings on recurrent varices. These observations should 
be taken into account in the management of cirrhotic patients in everyday clinical practice. 
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